Skip to main content
. 2017 Apr 20;189(2):250–258. doi: 10.1111/cei.12970

Figure 3.

Figure 3

Effect of Janus kinase (JAK) inhibition on neutrophil reactive oxygen species (ROS) production. (a) Preincubation with baricitinib and tofacitinib for 30 min did not affect the production of ROS by unprimed neutrophils in response to f‐Met‐Leu‐Phe (fMLP) (1 μM), but inhibited ROS production in healthy control neutrophils primed with granulocyte–macrophage‐colony stimulating factor (GM‐CSF) for 45 min (b, *P < 0·05). GM‐CSF priming did not increase ROS production in RA neutrophils, and JAK inhibitors had no effect on ROS production. (c) ROS production was increased by tofacitinib in response to phorbol‐12‐myristate‐12‐acetate (PMA) (100 ng/ml) in RA neutrophils (*P < 0·05). (d) Both baricitinib and tofacitinib increased ROS production in GM‐CSF‐primed neutrophils from healthy controls (*P < 0·05).